AstraZeneca is launching Airsupra (albuterol/budesonide) for the treatment or prevention of symptoms of asthma and to help prevent sudden severe breathing problems (asthma attacks) in people aged 18 years old and older.
Airsupra contains a short-acting beta2-agonist, to help relax the smooth muscles of the airways, and an inhaled corticosteroid, to help decrease inflammation in the lungs, the company said.
Priya Bansal, a physician and CEO at Asthma and Allergy Wellness Center said, “For over five decades, the medical community has used SABA-only rescue which does not address the inflammatory component of asthma. Now, with Airsupra available we can provide patients, especially those on maintenance therapy, another rescue option for managing their breakthrough symptoms. The MANDALA study has demonstrated how these patients can benefit from an as-needed anti-inflammatory rescue to treat their symptoms while helping to prevent an attack even if they are on ICS-containing maintenance therapy.”
Liz Bodin, vice president of U.S. Respiratory and Immunology at AstraZeneca said, “With Airsupra now available in the United States, we are taking an important step in our mission to revolutionize asthma for millions of people living with the disease. We are hopeful our innovative asthma rescue medicine can help alleviate the burden by addressing both symptoms and underlying inflammation simultaneously at the right time to reduce the risk of having a severe asthma attack.”